Background
Pancreatic cancer is considered one of the most aggressive cancers with poor prognosis. It is usually tardily diagnosed due to its atypical symptomatology, th...
Background
The first-line treatment in advanced pancreatic cancer (ACP) is well established by phase III studies, with protocols FOLFIRINOX (FF) and gemcitabine/ nab-pac...
Background
EGFR antibodies are efficient in the treatment of patients with RAS wild type metastatic colorectal cancer (mCRC). However, 25% of those patients resist to th...
Background
Colorectal cancer is a real public health problem, it ranks third among cancers in terms of frequency the world and second in terms of mortality. Several envi...
Background
Anlotinib, a novel multi-targeting tyrosine kinase inhibitor (TKI), has been investigated in a variety of malignant tumors and has shown efficacy in clinical ...
Background
The PI3K signaling pathway plays a key role in the pathogenesis of many cancer types, including colorectal cancer. The PI3K signaling pathway is deregulated d...
Background
It is estimated that about 2% to 5% of pancreatic malignant tumors are metastatic lesions. Lung, kidney and breast cancer as well as melanoma are the most com...
Background
Dual specificity phosphatases (DUSPs) are pivotal regulators of protein activation through dephosphorylating key molecules such as mitogen activated protein k...
Background
The rise of colorectal carcinoma in adolescents and young adults (AYA) is a growing global concern. Limited studies are available which have focused on colon ...
Background
Nearly a third of patients with curatively resected colorectal cancer experience recurrence. However, prognostic data do not discern sporadic early onset colo...